Production (Stage)
Arcutis Biotherapeutics, Inc.
ARQT
$13.98
$0.322.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 335.28% | 470.62% | 494.53% | 559.09% | 641.83% |
| Total Other Revenue | -93.15% | -1.38% | -7.96% | 13,709.52% | -- |
| Total Revenue | 100.03% | 229.74% | 182.84% | 1,032.90% | 1,545.18% |
| Cost of Revenue | 231.13% | 283.56% | 348.51% | 338.74% | 385.36% |
| Gross Profit | 90.14% | 224.82% | 171.18% | 1,204.73% | 1,906.77% |
| SG&A Expenses | 21.10% | 23.90% | 27.07% | 29.66% | 37.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.33% | 8.06% | 7.82% | -4.89% | -5.87% |
| Operating Income | 38.25% | 46.75% | 26.74% | 43.15% | 37.68% |
| Income Before Tax | 39.68% | 46.20% | 26.30% | 40.94% | 34.59% |
| Income Tax Expenses | -82.15% | -78.77% | -88.46% | -- | -- |
| Earnings from Continuing Operations | 40.34% | 46.58% | 27.01% | 39.92% | 33.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.34% | 46.58% | 27.01% | 39.92% | 33.56% |
| EBIT | 38.25% | 46.75% | 26.74% | 43.15% | 37.68% |
| EBITDA | 40.53% | 47.49% | 27.33% | 43.37% | 37.94% |
| EPS Basic | 64.22% | 70.23% | 59.00% | 60.54% | 48.75% |
| Normalized Basic EPS | 63.73% | 69.99% | 58.60% | 61.48% | 49.67% |
| EPS Diluted | 64.22% | 70.23% | 59.00% | 60.54% | 48.75% |
| Normalized Diluted EPS | 63.73% | 69.99% | 58.60% | 61.48% | 49.67% |
| Average Basic Shares Outstanding | 52.62% | 74.70% | 84.03% | 61.58% | 41.69% |
| Average Diluted Shares Outstanding | 52.62% | 74.70% | 84.03% | 61.58% | 41.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |